CD36 and type 2 diabetes mellitus: Although our insulin-resistant hiPSC-CMs are a model generated by replicating only some of the metabolic drivers of T2D,18 the magnitude of increase in CD36 S-acylation between the cardiomyocyte and in vivo models was conserved.